

Christian Eichelberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11492438/publications.pdf>

Version: 2024-02-01

25
papers

1,004
citations

567281

15
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

1460
citing authors

#	ARTICLE	IF	CITATIONS
1	Y-chromosome loss is frequent in male renal tumors. <i>Annals of Translational Medicine</i> , 2021, 9, 209-209.	1.7	13
2	Introduction of a New Score to Assess Surgical Efficiency in Holmium Laser Enucleation of the Prostate. <i>Urologia Internationalis</i> , 2020, 104, 914-922.	1.3	4
3	Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. Score in patients undergoing surgery for renal masses. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 249-257.	3.9	7
4	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e19-531.e25.	1.6	17
5	HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. <i>World Journal of Urology</i> , 2018, 36, 2035-2041.	2.2	36
6	REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. <i>Future Oncology</i> , 2015, 11, 2893-2903.	2.4	3
7	Î²III-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1561-1569.	2.2	14
8	SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. <i>European Urology</i> , 2015, 68, 837-847.	1.9	116
9	Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?. <i>Cancer</i> , 2015, 121, 1906-1907.	4.1	0
10	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. <i>Anticancer Research</i> , 2014, 34, 2255-61.	1.1	28
11	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. <i>World Journal of Urology</i> , 2013, 31, 847-853.	2.2	13
12	Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2948-2955.	5.1	25
13	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1268-1275.	4.1	48
14	Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. <i>BJU International</i> , 2010, 106, 478-483.	2.5	19
15	The Feasibility of Prostate Cancer Detection by Triple Spectroscopy. <i>European Urology</i> , 2009, 55, 376-384.	1.9	29
16	Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. <i>European Urology</i> , 2009, 55, 851-863.	1.9	132
17	Editorial Comment on: Topographical Anatomy of Periprostatic and Capsular Nerves: Quantification and Computerised Planimetry. <i>European Urology</i> , 2008, 54, 361.	1.9	0
18	Editorial Comment on: The Periprostatic Autonomic Nerves—Bundle or Layer?. <i>European Urology</i> , 2008, 54, 1116.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis. <i>European Urology</i> , 2008, 54, 1373-1378.	1.9	91
20	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. <i>European Journal of Cancer</i> , 2007, 43, 536-543.	2.8	77
21	Nerve Distribution along the Prostatic Capsule. <i>European Urology</i> , 2007, 51, 105-111.	1.9	142
22	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. <i>BJU International</i> , 2006, 98, 1204-1209.	2.5	62
23	The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2006, 49, 273-279.	1.9	45
24	Frozen Section for the Management of Intraoperatively Detected Palpable Tumor Lesions During Nerve-Sparing Scheduled Radical Prostatectomy. <i>European Urology</i> , 2006, 49, 1011-1018.	1.9	67
25	Indication, Technique and Outcome of Retropubic Nerve-Sparing Radical Prostatectomy. <i>EAU Update Series</i> , 2005, 3, 77-85.	0.5	15